Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2071 to 2085 of 2579 results for methods

  1. Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy [ID1264]

    Discontinued Reference number: GID-TA10365

    Technology appraisal guidance
    Discontinued

  2. Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

    Discontinued Reference number: GID-TA10536

    Technology appraisal guidance
    Discontinued

  3. Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

    Discontinued Reference number: GID-TA10539

    Technology appraisal guidance
    Discontinued

  4. Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]

    Discontinued Reference number: GID-TA10585

    Technology appraisal guidance
    Discontinued

  5. Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

    Discontinued Reference number: GID-TA10465

    Technology appraisal guidance
    Discontinued

  6. Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]

    Discontinued Reference number: GID-TA10480

    Technology appraisal guidance
    Discontinued

  7. Macular oedema (diabetic) - pegaptanib sodium [ID452]

    Discontinued Reference number: GID-TAG280

    Technology appraisal guidance
    Discontinued

  8. Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

    Discontinued Reference number: GID-TAG321

    Technology appraisal guidance
    Discontinued

  9. Constipation (opioid induced) - lubiprostone [ID646]

    Discontinued Reference number: GID-TAG367

    Technology appraisal guidance
    Discontinued

  10. Avelumab for maintenance treatment of advanced gastric or gastro-oesophageal junction cancer after platinum-based chemotherapy [ID2693]

    Discontinued Reference number: GID-TA10628

    Technology appraisal guidance
    Discontinued

  11. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued Reference number: GID-TAG395

    Technology appraisal guidance
    Discontinued

  12. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    Discontinued Reference number: GID-TA11000

    Technology appraisal guidance
    Discontinued

  13. Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]

    Discontinued Reference number: GID-TA11026

    Technology appraisal guidance
    Discontinued

  14. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued Reference number: GID-TA10066

    Technology appraisal guidance
    Discontinued

  15. Masitinib for treating amyotrophic lateral sclerosis [ID967]

    Discontinued Reference number: GID-TA10157

    Technology appraisal guidance
    Discontinued